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Abstract
Background: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths
worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population
was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are
unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C
viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to
screening, linkage to care and treatment, and cure.
Methods: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C
viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research
is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature.
Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups.
Results: Eleven potential subgroups were identified. There were no data available for two subgroups: generational
cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to
have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were
the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with
haemophilia and transplant recipients.
Conclusions: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards
eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other
health-care providers and availability of treatment in local pharmacies are central to improving the current situation
and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.
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Background
Infection with the hepatitis C virus (HCV) remains one of
the leading causes of chronic liver disease and liver-related
deaths worldwide [1, 2], prompting the World Health
Organization (WHO) in 2016 to define targets for eliminat-
ing it by 2030 [3, 4]. The estimated prevalence of chronic
HCV infection among the general Belgian population was
0.57% in 2015 [5]. However, estimates are based mostly on
modelling data, as recent population-based studies are
scarce and subject to selection bias [6]. Since 2014, Belgium
has had a ‘Hepatitis C Plan’ [7]. The plan was developed in
collaboration with healthcare professionals (e.g. gastroen-
terologists specialized in hepatology, representatives from
professional associations of gastroenterologists, doctors as-
sociated with AIDS referral centres, and representatives
from addiction treatment centres) and with patient associa-
tions. The main goals of the plan were: (1) to reduce trans-
mission; (2) to increase the number of HCV-positive
patients aware of their diagnosis; and (3) to enhance the pa-
tient care pathway and quality of life [7], and were listed up
in 23 different action points. Many action points, including
a screening policy and the collection of scientific data, have
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not yet been executed and it is unclear how the action
points will be evaluated [8, 9]. Therefore, it has been diffi-
cult to create an overview of HCV elimination efforts in
Belgium.
A practical, comprehensive approach to national
HCV elimination can benefit from population seg-
mentation in order to tailor concentrated elimination
efforts to specific population subgroups—a concept
known as ‘micro-elimination’ [10, 11]. These popula-
tion subgroups include children (under the age of 15
years), HCV/HIV-coinfected persons, birth cohorts,
haemodialysis (HD) patients, those living with haemo-
philia, men who have sex with men (MSM), migrants,
people with advanced liver disease, people who inject
drugs (PWID), prisoners, and transplant recipients
(Table 1) [10, 22]. However, accurate, up-to-date
prevalence data to inform strategic micro-elimination
planning are lacking in Belgium.
With direct-acting antiviral (DAA) therapy and its
≥95% cure rate, HCV elimination is achievable [23, 24].
Belgium based its 2015 guidelines for prescribing DAA
therapy on the fibrosis stage, restricting it to patients
with severe fibrosis or cirrhosis (F3–F4). Since January
2017 DAA therapy was reimbursable not only for pa-
tients starting treatment from the F2 fibrosis stage, but
for all patients with risk factors or comorbidities such as
hepatitis B virus (HBV)- or HIV-coinfection, haemo-
philia, and severe extrahepatic manifestations, as well as
patients on dialysis or those on a transplant waiting list
[9, 23–26]. Since the latest update in January 2019 HCV
treatment is reimbursed for every patient regardless of
the degree of fibrosis [27]. Currently, DAAs can be pre-
scribed and initiated only by a gastroenterologist and are
available only in a hospital pharmacy [26].
In this paper, we attempt to employ the best available
data to define the burden of HCV infection among key
subgroups in Belgium, identify information gaps among
these subgroups, and propose potential approaches for
screening, prevention, linkage to care, treatment and, ul-
timately, cure. To assess the feasibility of reaching the
WHO elimination goals, we further present mathemat-
ical modelling results.
Methods
A constrained optimization modelling approach was ap-
plied for developing the model in Excel. This modeling
approach is commonly applied in healthcare for pur-
poses such as capacity management, clinical decision
making, and optimal allocation of resources [28]. The
model was designed to address two objectives. The first
objective of this model is to demonstrate the number of
HCV patient needed to treat per year in order to reach
the WHO targets for HCV elimination given constraints
such as the number of known HCV patients, the country
specific annual incidence rate of HCV and the number
of years until the year 2030 is reached.
The first objective function is:
Χ Y 1þ Yð Þ
t
1þ Yð Þt−1 ¼ N
N= number of patients needed to treat per year to
reach the WHO HCV elimination goal by 2030.
X: number of HCV patient in a given year.
Y: country specific HCV incidence rate.
t: number of years.
Table 1 Target population for micro-elimination of HCV in Belgium
SUBGROUP Estimated number of Hepatitis c infections
Children (under age 15) Newly diagnosed (and reported) HCV cases in 2015: 19 cases aged
under 15 years of age [12]
Coinfected with HIV 353 (calculated, 2.4% of HIV-positive population) [13, 14]
Generational cohorts with high
prevalence (born 1945–1965)
No data
Patients on HD 297 (4% of patients on HD in Belgium) [15]
Haemophilia patients No national data; 11 patients remaining at the University Hospital Leuven
MSM No national data: 19 out of 1055 (1.8%) in 2017 at ITM Antwerp
Migrants from high-prevalence countries 18,607 estimated (range 9729-32,764) [16]
Patients with advanced liver disease 21,875 [17, 18]
PWID 2970 calculated used benchmark multiplier methodology [19]
Prisoners 1777 calculated (15.1% HCV-infected of 11,769 prisoners) [20, 21]
Transplant recipients 146 (12.6%) out of 1156 liver transplants between 2008 and 2012
[6]; 11 at one site [6]
Abbreviations: HCV hepatitis C virus; HD haemodialysis; MSM men who have sex with men; ITM Institute of Tropical Medicine; PWID people who inject drugs
Busschots et al. BMC Infectious Diseases          (2020) 20:181 Page 2 of 12
The second objective of the model is to demonstrate
the year in which HCV elimination will be reached with
the current treatment rate or alternative treatment rates.




1þ yð Þi ¼ 0
T = the year HCV elimination will be reached.
i = number of years.
C: number of HCV patient (= number of eligible patients
– number of patients treated).
y: country specific HCV incidence rate.
The estimates quantifying the subpopulations used in
the model to project were:
 the number of patients who would receive treatment
and the number of patients who would be left
untreated by the year 2030 based on the current
(3%) versus alternative (needed to meet the WHO
targets) rate (8%) of treatment per year.
 year in which HCV elimination will be reached in
that group with the current treatment rates or
alternative treatment rate;
The input parameters used were as follows:
 estimated number of HCV patients eligible for
treatment
 incidence rate of HCV infection
 rate of reinfection
 annual treatment rate
We searched the peer-reviewed (PubMed/Medline) and
grey literature (Google Scholar) between January 2012 and
August 2018 for data on HCV prevalence in Belgium in
key subgroups. The limits are set so that the emphasis is
on HCV elimination in the DAA era. Since 2012, DAA
treatment has been available in Belgium, initially in a study
context. Keywords included the subgroups affected by
HCV identified by Lazarus et al. (Table 1), variations in
HCV genotypes and differences between the subgroups in
Belgium [10, 11, 22]: hepatitis c virus (HCV), prevalence,
health policy, Belgium, children, people who inject drugs
(PWID), migrants, HIV, men who have sex with men
(MSM), prisoners, liver transplant, haemodialysis, haemo-
philia, generational cohort and advanced liver disease. Lit-
tle to no data have been published on the prevalence of
HCV in the key subgroups listened in Table 1. Therefore,
this research is primarily based on data provided by the
key stakeholders themselves listed as co-authors in this art-
icle, and not on a literature review. Ten national experts
were contacted to provide (unpublished) data mainly on
the prevalence of HCV in the aforementioned subgroups.
All experts graduated as medical doctors in different spe-
cialisations with a common interest in HCV. We reported
data for notified cases and estimates, as well as fibrosis
stage, where available. These data were supplemented with
original data from the 2017 Hep-CORE questionnaire [29].
Results
Children (under age 15)
There are no peer-reviewed sources available on the
current prevalence and incidence of HCV infection in
children in Belgium. The 2016 annual report from the
Belgian Public Health Research Institute pooled data of
a sentinel laboratory network in Belgium and reported
that fewer than 15 children were genotyped for HCV in
2015 (Table 2) [5]. Furthermore, based on pooled data
from all of the health insurance distributors in Belgium,
even fewer children received HCV serology testing in
2016 [30]. Alternatively, an attempt was made to calcu-
late the rate of mother-to-child transmission. Assuming
an incidence of 0.57% of HCV in adult patients in
Belgium and a rate of 100,000 births each year, 500
women infected with HCV give birth with a 5.0% risk of
Table 2 Number of children infected with HCV, treatment and cure rates in University Clinics Saint-Luc, Brussels
Age Patients (total, n) Treated (n) SVR reached (n)
< 15 years 3 months 1 0 0
13 months 1 0 0
3 years 2 1 1
4 years 1 1 1
5 years 3 0 0
8 years 2 2 2
13 years 5 5 5
Subtotal 15 9 9
> 15–18 years 10 – –
TOTAL 25 9 9
Abbreviations: SVR sustained virological response
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perinatal transmission [31]. This leads to an estimated
25 infected infants per year.
HIV-positive patients
The incidence of HCV in an HIV cohort in Antwerp was
estimated to be between 0.24 (2001) and 1.36 (2011) new
cases per 100 person-years, with a peak of 2.93 new cases
per 100 person-years in 2009 [32, 33]. The prevalence of
HCV/HIV coinfection among this cohort of close to 1400
MSM was 10% in 2017. In 2014, Belgium counted 14,719
people living with HIV (PLHIV) of whom 3% would be
HCV/HIV co-infected [13].
Men who have sex with men
Screening for HCV is not yet recommended in the HIV-
negative MSM population and no data are available on
the prevalence of HCV in this subgroup in Belgium.
Routine data from a screening centre for sexually trans-
mitted infections (STIs) in Antwerp, focusing on people
belonging to difficult-to-reach, high-risk groups (includ-
ing MSM, migrants and sex workers) show that in 2017,
19 out of 1055 people tested (1.8%) were HCV-positive.
Generational cohorts with high prevalence
In 2016, 1106 patients were screened for HCV antibodies
(Ab) at the emergency department (ED) of a tertiary hos-
pital in Ghent [34]. The overall prevalence of HCV Ab
was 1.9%. There was no significant difference in the preva-
lence of HCV in the different birth cohorts, and HCV
positivity was solely linked to a history of injecting drug
use. A second study was performed at the ED of Zieken-
huis Oost-Limburg (ZOL) Genk in 2017 [35]. In total,
2366 patients aged 18–70 years were screened for HCV
Ab and HCV ribonucleic acid (RNA). The prevalence was
1.31% for HCV Ab and 0.52% for HCV RNA. Two thirds
of the patients were born between 1955 and 1974. HCV
Ab positivity was linked to being a PWID, imprisonment,
and birth in an high-endemic country with an HCV Ab
prevalence > 2.9%.
Haemophilia patients
The University Hospital Leuven has one of the largest
groups of haemophilia patients in Belgium and is on
track to reach the WHO elimination goals, with 11 pa-
tients still left untreated of the initial 84 HCV RNA-
positive persons eligible for DAA treatment (Frederik
Nevens, Kathelijne Peerlinck, September 2018, oral com-
munication, unreferenced).
Haemodialysis patients
In the early 1990s, a high prevalence of HCV infection
among patients in HD units and nosocomial infections
was documented [36, 37]. Since then, strict hygienic
measures have been taken to reduce the risk of HCV
transmission through HD [38]. The HCV Ab prevalence
decreased from 13.5% (1991) to 6.8% (2000) in the Bel-
gian dialysis cohort (n = 1710) in 15 hospitals (p < 0.001)
[36]. More recently in 2014, an HCV prevalence of 4.1%
in Belgium was described in the multinational, multicen-
tre Dialysis Outcomes and Practice Patterns Study
(DOPPS) cohort [15]. Treatment is not always provided
to HD patients due to multi-morbidity, which carries a
higher risk of drug–drug interactions [39–41].
Migrants from high-prevalence countries
As previously described, one Belgian study at the ED of
ZOL, Genk confirmed that HCV Ab prevalence was in-
dependently associated with coming from a country with
high HCV endemicity [35]. According to a report of the
European Centre for Disease Prevention and Control in
2016, 11.4% of the Belgian adult population was born in
a country with high HCV Ab endemicity (HCV Ab
prevalence > 1%) [42].
Patients with advanced liver disease
Experts from the Belgian Association for Study of the
Liver (BASL) together with the Polaris Institute esti-
mated that, in 2014, there were 64,340 (0.57%) HCV-
infected patients, including 13,961 (21.7%) in F3 and
7914 (12.3%) in F4 stages in Belgium [43].
An estimation of the number of treated patients can
be made using the ‘Farmanet’ data from the National In-
stitute for Health and Disability Insurance. These pro-
vided the defined daily dose (DDD) of all antiviral
therapies distributed by pharmacies in Belgium for 2015
and 2016 (Table 3) [44]. Assuming that all Belgian pa-
tients with hepatitis are treated with antivirals accessed
in Belgium, we can estimate a range based on short and
long treatment duration of patients treated with reim-
bursed DAA therapy in 2015 and 2016 by dividing the
DDD through the number of days per treatment. Since
treatment duration can extend from 84 days to as many
as 168 days, which is likely in patients with cirrhosis
[45]. Of 21,875 estimated patients with advanced liver
disease, only 2323 were treated with DAA therapy in
2015–2016.
People who inject drugs
In Belgium, the population size of PWID was estimated
using a benchmark multiplier methodology in 2013 [19].
In 2015, there were an estimated 9080 PWID, 47% of
whom were engaged in harm reduction efforts, including
needle–syringe programs (NSP) and/or opioid substitu-
tion therapy (OST) [46]. Overall, 2970 PWID were
HCV-infected, with an estimated 160 new HCV infec-
tions in 2015.
Currently, there are different screening projects run-
ning in Brussels, Antwerp, Liège, and in the province of
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Limburg. The results of these will need to be combined to
provide data on the uptake of screening and treatment,
and to study the incidence of HCV after introduction of
DAA therapy. In a large, multicentre retrospective analysis
in 15 hospitals across Belgium, 35 patients on OST and 18
active PWID were treated between 2013 and 2015 with
DAA monotherapy [20]. This means < 1% of HCV-
infected PWID were being treated annually.
Prisoners
There were 11,769 prisoners in 34 Belgian prisons in 2014
[47]. The HCV Ab positivity rate among prisoners in
Belgium is estimated to be around 10–15%, according to a
retrospective study in one prison in Liège (Mémoire Virgi-
nie Minguet 2010–2011; unpublished). In this study, 3710
consecutive prison entrants between 2006 and 2008 were
screened for HCV Ab. Of them, 542 (14.6%) tested posi-
tive (Table 4). It is difficult to extrapolate these results to
other Belgian prisons, since the population can vary from
one prison to another.
Transplant recipients
Transplanted patients receive regular follow-up care in a
tertiary hospital. At the University Hospital Leuven, 40
patients received a liver transplant due to HCV-related
hepatocellular carcinoma (HCC) or end-stage liver dis-
ease since the beginning of recording in 1989 (Table 5).
Of them, only 15 still have HCV infection; seven have
multiple comorbidities, seven are living abroad and one
is lost to follow up.
Mathematical model
According to the mathematical model that was employed in
this study, none of the subgroups added to the model would
currently achieve HCV elimination by 2030. With the
current treatment rate of 3%, the first subgroups, namely
migrants, HD patients and prisoners, would reach HCV
elimination by 2056 at the earliest (Table 6). If Belgium is to
meet the WHO targets, the average percentage of patients
to be treated per year out of the total pool of patients who
require treatment needs to increase to 8% (Table 7).
Discussion
The targets set out by WHO for the elimination of viral
hepatitis by 2030 are highly ambitious and whether it is
possible for each Member State to reach these remains un-
clear. In Belgium, this study found that more effective ef-
forts are required. BASL recommends targeted screening
for the aforementioned key populations [17, 48]. Neverthe-
less, this is not yet being done in Belgium, notwithstanding
Table 3 Provision of defined daily doses of DAA therapy and estimated number of treated patients
2015 2016 Total
DDD (n) Total (n) DDD (n) Total (n) DDD (n) Total (n)
SOF 107,075 637–1275 37,075 221–441 144,150 858–1716
SOF/LDV 1036 6–12 21,172 126–252 22,208 132–264
OBV/PTV/r 8988 54–107 19,844 118–236 28,832 172–343
Total 117,099 697–1394 78,091 465–929 195,190 1162-2323
Abbreviations: DDD defined daily dose; SOF sofosbuvir; LDV ledipasvir; OBV/PTV/r ombitasvir, paritaprevir and ritonavir
Table 4 Baseline characteristics of HCV Ab-positive prisoners in Liège
Variable n (%) M ± SD p-value
Age (years) Total (M ± SD) 542 35.7 ± 7.37
Male (M ± SD) 460 (84.6%) 35.9 ± 7.46 0.29
Female (M ± SD) 84 (15.4%) 35.0 ± 6.85
Ethnicity Western Caucasian 425 (78.1%) – –
North African 86 (15.8%)
Eastern Caucasian 31 (5.7%)
Southern African 2 (0.4%)
Coinfection HIV No 515 (94.7%) – –
Yes 29 (5.3%)
Drug abuse No 61 (11.5%) – –
Yes 471 (88.5%)
Reinfection after previous cure in prison (n = 15) No 10 (66.6%) – –
Yes 5 (33.3%)
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the serious health and economic burden associated with
chronic HCV infection [49]. Despite the efforts that were
made to prepare the Belgian Hepatitis C plan, HCV elimin-
ation among these groups has not been documented to
date, and there is no surveillance available to monitor the
elimination of HCV infection [7, 8]. Additionally, DAA
treatment has been available since 2015 and, although it is
only reimbursed for every patient regardless of the degree
of fibrosis since January 2019 [27]. The HCV prevalence in
the general Belgian population is low, although based on
the limited data available, it seems slightly higher in several
subgroups. Therefore, it may be more feasible to approach
these smaller populations with a micro-elimination
approach. It is less daunting, less complex and less costly
than full-scale country-level initiatives [10]. Further, if this
micro-elimination strategy initially focuses on patients
already in the health system, prevention, screening and
treatment interventions can often be provided more easily.
Stakeholders who are not traditionally involved with viral
hepatitis could be more interested in engaging due to this
efficient way of increasing diagnosis and treatment in se-
lected populations.
Addressing micro-elimination in subpopulations
Children (under the age of 15)
Worldwide, 5 million children under the age of 15 are
chronically infected with HCV [50]. A higher infection
prevalence (1.8–5%) is reported in low- and middle-
income countries and a lower prevalence is reported
(0.05–0.36%) in high-income countries [50, 51]. The pri-
mary source of infection among children is mother-to-
child transmission [52]. Testing for HCV RNA in chil-
dren born to mothers with chronic HCV infection is re-
imbursed in Belgium. Infected infants often experience
spontaneous clearance, RNA tests are expensive and
there is no safe HCV treatment yet available for children
under the age of 3 years. Therefore, experts recommend
that children be tested at the age of 18 months or older
[53]. There are no recommendations in Belgium yet on
the use of DAA therapy in children, nor is there infor-
mation on the follow up of children with chronic HCV
infection.
Patients who are already in the health-care system
Patients with advanced liver disease In 2017, 46% of
all European countries still had a reimbursement restric-
tion requiring a fibrosis stage of ≥F2 [23, 24]. Recently, a
consensus statement redefined these fibrosis stages using
different diagnostic tools [18]. Treating patients with more
severe liver disease (F2–F4) is effective in reducing all-
cause and liver-related morbidity and mortality; however,
Table 5 Micro-elimination of HCV in transplant recipients in
Belgium
Transplant UZ Leuven (n)
Total liver transplants 1360
Liver transplantation due to HCV: 169
HCC 40
Decompensated cirrhosis 129
Patients still alive 66
Relapse of HCV after transplant 65
Treated for HCV relapse 55
IFN 21
DAA 34
Cured of HCV relapse 50
IFN 16
DAA 34
Patients with HCV no longer in follow-up 15
Living abroad 7
No treatment (comorbidity) 7
Loss to follow-up 1
Abbreviations: HCV hepatitis C virus; HCC hepatocellular carcinoma; IFN
interferon; DAA direct-acting antiviral (drug)
Table 6 Mathematical modelling results based on current Belgian situation
RESULTS BASED ON CURRENT SITUATION
POPULATION
Subgroup
Number of patients to treat at
















PLHIVa 282 92 190 67% 7 2057
HD patientsa 238 78 160 67% 6 2056
Migrants b 14,969 4882 10,087 67% 375 2056
Patients with advanced
liver diseaseb
17,500 5722 11,778 67% 440 2057
PWIDb 3656 996 2660 73% 77 2314
Prisonersb 1422 465 957 67% 36 2056
a Reported bEstimated
Abbreviations: PLHIV people living with HIV; HD haemodialysis; PWID people who inject drugs
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it will have less impact on transmission, and treating only
these patients will be insufficient to reach the WHO tar-
gets [54]. Further, we still need to define when a patient
will not benefit from DAA therapy and requires a trans-
plant. Following the EASL guidelines of 2018, a trans-
plantation before HCV treatment is recommended if the
patient has decompensated cirrhosis and a MELD score ≥
18–20, because the probability of significant improvement
in liver function and delisting is low [55–59].
Haemophilia patients The prevalence of HCV infection
in haemophilia patients varies by country, reaching as
high as 100% in some reports [60]. Up to 20–30% of
these patients develop end-stage liver disease or HCC,
which has become the most prevalent cancer in this sub-
group [61]. Since January 2017, patients without any on-
going high-risk behaviour for acquiring HCV could be
treated with a minimal risk of reinfection in Belgium. In
Ireland, more than 90% of all haemophilia patients with
HCV infection were cured with a DAA regimen. As a re-
sult, HCV infection was eradicated in this Irish subgroup
in 2016 [62]. At the University Hospital Leuven, elimin-
ation has almost been reached, with just 11 patients un-
treated. However, we should have a monitoring tool to
generate these data nationwide.
Haemodialysis patients Overall, the HCV Ab preva-
lence has declined in HD patients, according to the
DOPPS cohort [15]. Nevertheless, between 2012 and
2014, only 1.7% of DOPPS patients who were HCV Ab-
positive were treated at any point during study follow
up, and 35% of facilities used isolation stations for HCV-
infected patients, a significant, yet debated, logistical
burden [39]. Importantly, HCV Ab-positive patients had
higher adjusted rates of mortality (HR = 1.14, 95% confi-
dence interval [CI]: 1.06–1.23) and time to first
hospitalization (HR = 1.10, 95% CI: 1.06–1.15) [40]. Since
the introduction of strict hygienic measures, there are
only around 297 HCV-infected HD patients remaining
in Belgium [15]. Elimination of HCV is feasible in this
subgroup as they are under strict follow up, regularly
screened for HCV, and have unrestricted access to ther-
apy with DAAs. Furthermore, the availability of a new,
well-tolerated pangenotypic treatment regimen will
make DAA treatment possible for all HD patients [62].
The elimination of HCV would have the additional ad-
vantage of preventing further nosocomial transmission
within HD units [63].
Transplant recipients There has been a significant de-
crease in the prevalence of patients receiving a trans-
plant due to evolving antiviral therapy [64]. The new
DAA regimens allow treatment of patients with cirrho-
sis, with a MELD score of up to 18 [65]. Collection of
data is necessary to document this success and there is
not yet a centralised database of transplanted patients in
Belgium. Currently, Belgium is on track to eliminating
HCV in this subgroup by 2030.
HIV-positive patients A systematic review estimated
that there were approximately 2,278,400 HIV/HCV-
coinfected persons globally, accounting for an overall co-
infection prevalence of 6.2% among PLHIV in 2016 [14].
Since 2017, all HIV/HCV-coinfected patients can be
treated with DAA therapy in Belgium. This creates an
opportunity to eliminate HCV in this well-defined and
well-linked-to-care cohort of patients. However, the ef-
fect of DAA therapy on the incidence of HCV among
PLHIV has not been thoroughly studied. This remains a
concern, as reinfection is not uncommon [66]. We can
only speculate that reinfection would be increased in the
subgroup compared to the general population in
Belgium as we lack data on this subject. Systematic test-
ing has proven to be effective in achieving high rates of
HCV diagnoses [67]. All PLHIV in Belgium who engage
in sexual risk behaviour and visit an outpatient clinic in
an AIDS reference centre should routinely be screened
for HCV infection at least once a year [68].
People potentially at risk due to demographic
characteristics
Generational cohorts with high prevalence The Cen-
ters for Disease Control and Prevention (CDC) recom-
mended one-time testing for all persons born between
1945 and 1965 in the United States of America (USA)
[69]. The CDC estimated that in the USA, 800,000 per-
sons unaware of their HCV infection would be identified
Table 7 Mathematical modelling results-based simulation to
reach target
RESULTS-BASED SIMULATION TO REACH TARGET
SUBGROUP Number of patients needed to
treat per year between 2018











aTreatment target was assumed at treating 80% of the
HCV-infected population
Abbreviations: PLHIV people living with HIV; HD haemodialysis; PWID people
who inject drugs
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and more than 120,000 HCV-related deaths would be
averted if these persons were linked to appropriate HCV
care [70, 71]. Due to the lack of data it is unclear whether
this would be comparable to the Belgian population. A
study on birth cohort variation in liver cirrhosis between
eight European countries calculated that more than 50% of
all patients were born between 1955 and 1974, while ap-
proximately 70% were born between 1950 and 1979 [6,
72]. In a recent Belgian study conducted at the ED of ZOL
Genk, there was no significant difference in the prevalence
of HCV Ab in the different birth cohorts. HCV Ab positiv-
ity was linked solely to a history of injecting drug use [35].
Targeting males born between 1955 and 1974 in Belgium
could be a possible screening approach, though only if we
were not able to focus on screening high-risk groups. In
general, there remains a lack of prospective, representative
studies powered to analyse the distribution of HCV by
birth cohort, while correcting for confounders such as risk
behaviour.
Migrants from high-prevalence countries In 2016,
Belgium received 18,710 asylum requests [16]. Of these,
2766 people from Syria requested asylum and 724 people
from Russia, both countries with chronic HCV infection
rates of > 2.9%. Approximately 100 of those migrants
would be chronically infected with HCV. The average
HCV Ab prevalence for migrants in Belgium was estimated
at 1.8%, meaning 18,607 (9729–32,764) migrants would be
HCV Ab-positive. It is difficult to state whether universal
screening of migrants for HCV would be cost effective
[73]. Models have shown that universal screening would
not be cost effective, upon which experts have recom-
mended that migrant populations be screened only if the
HCV prevalence is > 2.9% in the country of origin [74].
Currently, there are no real-life data available on the preva-
lence of HCV infection in, or linkage to care or treatment
of HCV-infected, migrants in Belgium.
People with high-risk behaviour
People who inject drugs In most high-income countries,
PWID are at the heart of the ongoing HCV epidemic [75].
To avert future liver disease and new infections, prevention
of HCV transmission among PWID is crucial [76]. The
Belgian Hepatitis C Plan, BASL and European Association
for Study of the Liver (EASL) guidelines recommend
screening PWID for HCV infection, yet there is no reim-
bursement for repeated HCV RNA testing [7, 25, 26, 45].
The European Monitoring Centre for Drugs and Drug Ad-
diction has stated that combined OST and high-coverage
NSP can reduce HCV incidence by up to 80% [77–81].
The HCV incidence remains high in many settings, par-
ticularly in the first several years after a person starts
injecting drugs [82–85]. Diagnosis rates have increased
through awareness campaigns, screening programmes pro-
viding free and anonymous testing to PWID, and training
of general practitioners to identify risk factors. Further-
more, moving testing out of hospitals and into addiction
clinics, harm reduction programmes and other services tar-
geting PWID, as well as referring them directly to special-
ists from these settings, have proven to be the best paths to
reaching this group effectively [46, 80, 83]. A similar pro-
ject on outreach and treatment under one roof is currently
conducted in Antwerp and Limburg. In a case manage-
ment study in Limburg, results revealed that some target
groups were not reached, such as young opiate injectors
who had not yet contacted centres such as CAD Limburg
or Free Clinic Antwerp, and injectors using injectable
drugs other than heroin [86]. At present, a targeted screen-
ing strategy is being conducted only with the help of exter-
nal funding through projects. Additionally, if DAAs could
be prescribed by general practitioners and were available in
local pharmacies, the threshold for linkage to care would
be lower. Improving harm reduction and scaling up treat-
ment uptake to ≥10% annually is an absolute necessity to
reach the targets of WHO [3, 21].
Prisoners In prisons, the estimated HCV Ab prevalence
is 15.4% in Western Europe, and 20.7% in Eastern Eur-
ope [87]. However, these estimates are based on few
studies, and could even be an underestimation as was
shown in Ukraine [88]. Awareness campaigns and
screenings have shown an improvement in the diagnosis
rate within prisons. Interventions in France, Italy and
Scotland have been successful when prisoners could be
treated directly in the prisons [67]. A national plan could
be easily implemented by the Ministry of Health in con-
junction with the Ministry of Justice. This plan should
not only include screening of prisoners but also training
of health-care providers in prisons and defining the
methodology to access treatment. All prisoners in
Belgium have the right to get treated for an HCV infec-
tion. However, there is no universal screening procedure
yet. For further testing (FibroScan®), prisoners need to
be transferred to one of the two prisons with a hospital-
isation unit (Liège and Bruges). Low treatment uptake in
prison could be explained by difficulties in transfer to
the referral centres but also by different reasons (Mém-
oire Virginie Minguet 2010–2011; unpublished) such as
a short length of incarceration and reluctance to take
treatment. As all health-care costs are provided by the
Federal Department of Justice, large-scale screening and
treatment is not a priority. Due to the lack of data, it is
not clear how much overlap there is between prisoners
and PWID or also the migrant population. This is im-
portant to know given that where there is overlap and
we can treat all infected prisoners then we can also
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reduce the number of infected individuals in the over-
lapping risk groups.
Men who have sex with men Studies from large cities
suggest that HIV-negative MSM are also at risk for HCV
infection, especially those on pre-exposure prophylaxis
(PrEP) [89–92]. PrEP is effective in reducing the inci-
dence of HIV among people who practise high-risk sex-
ual behaviour, though it does not protect them against
other STIs such as HCV. A generalised screening
through dried blood spots in Barcelona did not detect
any incident HCV in this subgroup. In contrast, high-
risk behaviour and the incidence of other STIs suggested
that periodic screening could be necessary in MSM [93].
Screening the specific subgroup with high-risk behaviour
on PrEP is needed and is currently part of the reim-
bursement criteria for PrEP medication.
Mathematical model
According to the mathematical model that was used in
this study, none of the subgroups added to the model
would currently achieve HCV elimination by 2030. The
focus of the model is ‘treatment’ as since January 2019
all infected patients in Belgium can be treated regardless
of fibrosis stage. Nevertheless, we must keep in mind
that HCV elimination goals also relate to the diagnosis
of the undiagnosed. Several studies on this subject are
currently ongoing in Belgium. Therefore, this is not dis-
cussed in this article.
Limitations
This study is based on grey literature provided by national
experts and a scientific literature review. Given the lack of
available data, it is not a comprehensive picture of the
current situation in Belgium. The population groups men-
tioned in the study are not uniform. For example, the age
of haemophilia patients can greatly influence HCV rates.
It is not clear how much overlap there is between the dif-
ferent subgroups described in this study. In the event of
an overlap, the treatment of one group may contribute to
a reduction in infection in another subgroup.
The model developed for this study serves its purpose:
to broadly determine if Belgium is on track to eliminating
HCV in specific affected populations. This differs from
dynamic transmission models by not taking into account
the effects of treatment outcomes with anti-HCV medica-
tions or HCV death rates, among other factors. The model
assumes an incidence of 2 per 100 person-years and
reinfection rate of 2.3% in the PWID population, while
due to lack of data, it assumes no additional HCV infec-
tions in the other subgroups [94, 95]. Nevertheless, it pro-
vides a clear picture of the current situation, which
urgently needs to be improved.
Conclusion
In Belgium, reliable data are scarce on the subgroups in-
vestigated in this study. Many are already in specialist
care and, as such, present unique and important oppor-
tunities to move toward HCV elimination, given that
they are not restricted from treatment. Currently, only
those living with haemophilia and transplant recipients
are on track for reaching HCV elimination by 2030. In
contrast, none of the subgroups added to the model
would achieve HCV elimination by 2030 at the current
treatment rate. To eliminate HCV, more people must be
tested and linked to care, and the average percentage of
patients to be treated per year out of the total pool of
patients to be treated needs to be fixed at a minimum of
8% of the current patient pool. Removing HCV treat-
ment reimbursement restrictions in January 2019 was a
big step forward. In addition, creating a centralised HCV
database and constructing a national continuum-of-care
figure for each group would be important contributions
to improving the current situation. Another challenge is
access to DAA therapy. At present, it can be prescribed
and initiated only by a gastroenterologist and is available
only in a hospital pharmacy. If in the future DAA ther-
apy could be prescribed by other health-care profes-
sionals and available in local pharmacies as well,
treatment access would improve and patients would be
able to receive their medication more conveniently. Ul-
timately, elimination will be challenging without a vac-
cine, and therefore adequate prevention measures,
including harm reduction for PWID, must be accessible
through the country.
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